Pulse Biosciences (PLSE) Fundamental Analysis: Revenue, Earnings & Valuation

0.91 / 10

Underperform

Fundamental assessment rates PLSE as Underperform, scoring only 0.9/10. Profit‑to‑market value appears modestly positive, yet revenue‑MV and cash‑MV are negative, and key profitability ratios (ROA, margins) are deeply negative. Overall, the company shows deficient financial health and limited growth potential.

Analysis Checks(1/10)

Revenue-MV

Value-6.23

Score0/3

Weight16.44%

1M Return-4.18%

ROA (%)

Value-64.12

Score1/3

Weight3.43%

1M Return-0.82%

Net cash flow from operating activities / Operating revenue (%)

Value-15463.43

Score0/3

Weight18.20%

1M Return-6.63%

Profit-MV

Value0.66

Score2/3

Weight-15.52%

1M Return3.09%

Annualized net profit margin on total assets (%)

Value-64.12

Score1/3

Weight3.43%

1M Return-0.82%

EBIT / Total operating revenue (%)

Value-21997.43

Score0/3

Weight18.20%

1M Return-5.19%

Asset-MV

Value-0.55

Score0/3

Weight13.50%

1M Return-3.44%

Net profit / Total operating revenue (%)

Value-20794.57

Score0/3

Weight18.53%

1M Return-6.68%

Cash-MV

Value0.02

Score1/3

Weight14.72%

1M Return-4.16%

Net profit / Total profit (%)

Value100.00

Score1/3

Weight9.09%

1M Return-2.39%

Is PLSE fundamentally strong?

PLSE scores 0.91/10 on fundamentals and holds a Premium valuation at present. Backed by its -74.45% ROE, 0.00% net margin, -21.51 P/E ratio, 19.41 P/B ratio, and -17.39% earnings growth, these metrics solidify its Underperform investment rating.